CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals.
Explore this issueDecember 2018
Also by this Author
They also recounted recent victories in the policy realm by the ACR—among them, changes to reimbursement for biosimilars and the easing of cuts to imaging reimbursement—which they say show stepping into an advocacy role can bring results that matter.
The call to action came in a session at the 2018 ACR/ARHP Annual Meeting.
Among many legislative achievements over the past year, according to Angus Worthing, MD, chair of the ACR’s Government Affairs Committee, three were spearheaded by the ACR. One was to get the federal government to restart premium processing for physicians needing H1-B visas, which apply mostly to foreign-trained physicians practicing or finishing their training and wanting to practice in the U.S.